Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure (NCT06831825)
A Phase I Study of Safety and Preliminary Efficacy of YAP101 in Subjects With Ischemic Heart Failure and Reduced Ejection Fraction
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial investigates the safety and preliminary effectiveness of YAP101, a gene therapy designed to improve heart function in adults with ischemic heart failure and reduced ejection fraction (HFrEF). Ischemic heart failure, often resulting from a prior heart attack, leads to poor heart function and quality of life. Current treatments are limited, and there is an urgent need for new therapies. YAP101 works by delivering a gene therapy using a specialized vector to heart cells, targeting a pathway involved in heart repair. By temporarily activating heart muscle regeneration, YAP101 aims to restore damaged tissue, reduce scarring, and improve the heart's pumping ability. The study will enroll participants who will receive a one-time dose of YAP101 via a minimally invasive cardiac injection. Researchers will monitor participants over 12 months to assess safety and changes in heart function, exercise tolerance, and quality of life.
Who can join: Review the eligibility criteria below.
Location: Texas Heart Institute — Houston, Texas
Age range: 18 Years to 79 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Texas Heart Institute — Houston, Texas
📞 Contact the Study Coordinator
Phone: (713) 609-1928
Email: info@yaptx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Heart Failure With Reduced Ejection Fraction
- Study of JK07 in Patients With Chronic Heart Failure — Alexander City, Alabama
- A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction — Bradenton, Florida
- Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure — Baltimore, Maryland
- PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction — Charlottesville, Virginia
- Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure — Overland Park, Kansas
- Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure — Tulsa, Oklahoma
Explore by condition: All Heart Failure With Reduced Ejection Fraction clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.